A randomised controlled trial to prevent smoking relapse among recently quit smokers enrolled in employer and health plan sponsored quitlines.
A randomised controlled trial to prevent smoking relapse among recently quit smokers enrolled in employer and health plan sponsored quitlines.
复制标题
一项随机对照试验，旨在防止加入雇主和健康计划赞助的戒烟热线的最近戒烟者复吸。
DOI：
10.1136/bmjopen-2014-007260
复制
发表时间：
2015
期刊：
影响因子：
2.9
通讯作者：
Zbikowski,SusanM
中科院分区：
文献类型：
--
作者：
McDaniel,AnnaM;Vickerman,KatrinaA;Stump,TimothyE;Monahan,PatrickO;Fellows,JeffreyL;Weaver,MichaelT;Carlini,BeatrizH;Champion,VictoriaL;Zbikowski,SusanM
ObjectiveTo test adding an interactive voice response (IVR)-supported protocol to standard quitline treatment to prevent relapse among recently quit smokers.DesignParallel randomised controlled trial with three arms: standard quitline, standard plus technology enhanced quitline with 10 risk assessments (TEQ-10), standard plus 20 TEQ assessments (TEQ-20).SettingQuit For Life (QFL) programme.Participants1785 QFL enrolees through 19 employers or health plans who were 24+ h quit.InterventionsQFL is a 5-call telephone-based cessation programme including medications and web-based support. TEQ interventions included 10 or 20 IVR-delivered relapse risk assessments over 8 weeks with automated transfer to counselling for those at risk.Main outcome measuresSelf-reported 7-day and 30-day abstinence assessed at 6-month and 12-month post-enrolment (response rates: 61% and 59%, respectively). Missing data were imputed.Results1785 were randomised (standard n=592, TEQ-10 n=602, TEQ-20 n=591). Multiple imputation-derived, intent-to-treat 30-day quit rates (95% CI) at 6 months were 59.4% (53.7% to 63.8%) for standard, 62.3% (57.7% to 66.9%) for TEQ-10, 59.4% (53.7% to 65.1%) for TEQ-20 and 30-day quit rates at 12 months were 61.2% (55.6% to 66.8%) for standard, 60.6% (56.0% to 65.2%) for TEQ-10, 54.9% (49.0% to 60.9%) for TEQ-20. There were no significant differences in quit rates. 73.3% of TEQ participants were identified as at-risk by IVR assessments; on average, participants completed 0.41 IVR-transferred counselling calls. Positive risk assessments identified participants less likely (OR=0.56, 95% CI 0.42 to 0.76) to be abstinent at 6 months.ConclusionsStandard treatment was highly effective, with 61% remaining abstinent at 12 months using multiple imputation intent-to-treat (intent-to-treat missing=smoking quit rate: 38%). TEQ assessments identified quitters at risk for relapse. However, adding IVR-transferred counselling did not yield higher quit rates. Research is needed to determine if alternative designs can improve outcomes.Trial registration numberNCT00888992.
登录
查看更多内容
由杂交瘤抗体鉴定出的人类类风湿因子的常见独特位。
影响因子：
3.6
作者：
Carson,DA;Fong,S
通讯作者：
Fong,S
人单克隆 IgM（蛋白质 WEA）Fv 区的氨基酸序列，具有针对克雷伯氏菌多糖 K30 和 K33 中 3,4-丙酮酰化半乳糖的抗体活性。
DOI：
10.1073/pnas.80.15.4837
发表时间：
1983
影响因子：
11.1
作者：
Goñi,F;Frangione,B
通讯作者：
Frangione,B
类风湿因子和小鼠的二次免疫反应 II。
影响因子：
5.4
作者：
P. Coulie;J. Van Snick
通讯作者：
J. Van Snick
免疫球蛋白 M 重链和轻链的体外重组
影响因子：
3.7
作者：
R. Schrohenloher;R. Hester
通讯作者：
R. Hester
DOI：
10.1084/jem.139.1.128
发表时间：
1974-01-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Kunkel HG;Winchester RJ;Joslin FG;Capra JD
通讯作者：
Capra JD